Cyclacel Pharmaceuticals, Inc. (CYCC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. ...

Investors might want to bet on Cyclacel Pharmaceuticals, Inc. (CYCC) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ye ...

- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action - BERKELEY HEIGHTS, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced a presentation by independent investigators of preclinical data demonstrating therapeutic potential of fadraciclib, the Company's cyclindependen ...

The data showed that CRC PDOs were more sensitive to fadraciclib treatment than either chemotherapy or palbociclib. The investigators demonstrated fadraciclib's ability to inhibit both CDK2 and CDK9, cause anaphase catastrophe, downregulate MYC protein levels and induce apoptosis. These findings translated to significant tumor growth inhibition by fadraciclib in matched CRC PDX models. The study concluded that fadraciclib has potential as a therapy for advanced CRC and that CDK2/9 inhibition impacts multipl ...

Financial Data and Key Metrics Changes - As of March 31, 2024, pro-forma cash and cash equivalents totaled $9.9 million, which includes proceeds from a private placement and $0.8 million from the UK R&D Tax Credit Claim for 2023. Cash and cash equivalents decreased to $2.8 million from $3.4 million as of December 31, 2023 [8] - Net cash used in operating activities was $0.5 million for Q1 2024, compared to $6.9 million for the same period in 2023 [8] - Net loss for Q1 2024 was $2.9 million, down from $5.8 million in Q1 2023, indicating a reduction in expenditures as resources are concentrated on the Fadra Phase 2 study [11] Business Line Data and Key Metrics Changes - Research and development (R&D) expenses were $2.8 million for Q1 2024, down from $5.7 million in Q1 2023. R&D expenses related to Fadra were $1.8 million, compared to $4.1 million in the same period last year [9] - Expenses related to plogo decreased to $1 million in Q1 2024 from $1.4 million in Q1 2023 due to a pause in the 140-101 study [9] Market Data and Key Metrics Changes - The company is focusing on patients with CDKN2A or B alterations, which are associated with several solid tumors and T-cell lymphomas, indicating a targeted approach in a market with high unmet medical needs [15][16] Company Strategy and Development Direction - The company is pursuing a precision medicine approach for Fadra, targeting patients with specific chromosomal abnormalities. The Phase 2 study is evaluating patients based on their mutational profile and prior Phase 1 activity [15] - Key milestones include reporting data from the dose escalation stage of the 065-101 study at the ASCO 2024 Annual Meeting and initial clinical activity from the Phase 2 proof of concept part later in 2024 [26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing Phase 2 study and the potential for Fadra to address significant unmet medical needs in cancer treatment [15][16] - The company anticipates that its current cash resources will fund planned programs into Q4 2024, indicating a stable financial outlook for the near term [11] Other Important Information - The company has opened additional sites for the Phase 2 study to expedite patient enrollment, with expectations to deliver initial results by the second half of 2024 [5][15] Q&A Session Summary Question: What are the expectations for the fadraciclib 101 study at ASCO? - Management plans to present nearly the totality of the dose escalation portion of the study, including safety and efficacy data [12][13] Question: What is the timeline for the proof of concept Phase 2 portion of the study? - The company anticipates enrolling both cohorts by the end of the year, with additional T-cell lymphoma sites recently opened [29] Question: How are patients with mutations identified for the study? - The mutations are part of standard panels, and no companion diagnostic is needed, although data is being collected for future regulatory discussions [31]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number 000-50626 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ CYCLACEL PHARMACEUTICALS, INC. (Exact name of registrant as specif ...

Exhibit 99.1 Cyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib - - First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of Concept Study - - Balance Sheet Bolstered with $8.0 million Private Placement Priced At-The-Market Under Nasdaq Rules - - Management to Host Conference Call at 4:30 pm EDT Today ...

BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (888) 632-3384 / international call: (785) 424-1794 A ...

BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (888) 632-3384 / international call: (785) 424 ...

BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it has closed its previously announced private placement for the purchase and sale of 4,968,945 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 4,968,945 shares of common stock and short-term s ...